Last reviewed · How we verify
PET Scan with [11C]ABP688
[11C]ABP688 is a positron emission tomography (PET) tracer that binds to metabotropic glutamate receptor 5 (mGluR5) to enable imaging of mGluR5 expression in the brain.
[11C]ABP688 is a positron emission tomography (PET) tracer that binds to metabotropic glutamate receptor 5 (mGluR5) to enable imaging of mGluR5 expression in the brain. Used for PET imaging of mGluR5 expression in the brain for research and diagnostic purposes, Investigation of neurological and psychiatric disorders including Alzheimer's disease, Parkinson's disease, and schizophrenia.
At a glance
| Generic name | PET Scan with [11C]ABP688 |
|---|---|
| Sponsor | Stony Brook University |
| Drug class | PET imaging agent / Radiotracer |
| Target | mGluR5 (metabotropic glutamate receptor 5) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry / Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
[11C]ABP688 is a carbon-11 labeled radiotracer designed to selectively bind to mGluR5, a G-protein coupled receptor involved in glutamatergic neurotransmission. The radioactive carbon-11 allows visualization of mGluR5 distribution and density in the central nervous system using PET imaging. This enables non-invasive assessment of mGluR5 availability in neurological and psychiatric disorders.
Approved indications
- PET imaging of mGluR5 expression in the brain for research and diagnostic purposes
- Investigation of neurological and psychiatric disorders including Alzheimer's disease, Parkinson's disease, and schizophrenia
Common side effects
- Radiation exposure (minimal from diagnostic dose)
- Injection site reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PET Scan with [11C]ABP688 CI brief — competitive landscape report
- PET Scan with [11C]ABP688 updates RSS · CI watch RSS
- Stony Brook University portfolio CI